Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients ; volume:6 ; number:4 ; day:19 ; month:8 ; year:2019 ; pages:521-528 ; date:12.2019
Rheumatology and therapy ; 6, Heft 4 (19.8.2019), 521-528, 12.2019
- Creator
-
Lubrano, Ennio
Perrotta, Fabio Massimo
Scriffignano, Silvia
Coates, Laura C.
Helliwell, Philip
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-019-00171-w
- URN
-
urn:nbn:de:101:1-2020031405480118363115
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:59:36+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lubrano, Ennio
- Perrotta, Fabio Massimo
- Scriffignano, Silvia
- Coates, Laura C.
- Helliwell, Philip
- SpringerLink (Online service)
Other Objects (12)
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis
Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission
Treatment recommendations for psoriatic arthritis
Macrophage dysfunction in Psoriatic Arthritis
Lupus hands mimicking psoriatic arthritis
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis
Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission
Treatment recommendations for psoriatic arthritis
Macrophage dysfunction in Psoriatic Arthritis
Lupus hands mimicking psoriatic arthritis
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis
Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission
Treatment recommendations for psoriatic arthritis
Macrophage dysfunction in Psoriatic Arthritis